HomeInsightsStock Comparison

Marksans Pharma Ltd vs Unichem Laboratories Ltd Stock Comparison

Marksans Pharma Ltd vs Unichem Laboratories Ltd Stock Comparison

Last Updated on: May 22, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 250 as of 22 May 09:09.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 yearsThe P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 yearsThe Market Cap of Unichem Laboratories Ltd changed from ₹ 1065 crore on March 2020 to ₹ 3439 crore on March 2024 . This represents a CAGR of 26.41% over 5 years.
  • The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15% The revenue of Unichem Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 546.71 crore. This represent the decline of -100%.
  • The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61% The ebitda of Unichem Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 99.14 crore. This represent the decline of -100%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% The net profit of Unichem Laboratories Ltd changed from ₹ -0.67 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 yearsThe Dividend Payout of Unichem Laboratories Ltd changed from -50 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Unichem Laboratories Ltd

  • Unichem Laboratories Limited is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients.
  • The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division.
  • The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia).
  • The Baddi plant was approved by UK MHRA and MCC (South Africa).
  • The company received ISO 9001:2000 for all their plants and corporate office.

Marksans Pharma Ltd News Hub

News

Board of Marksans Pharma recommends final dividend

Marksans Pharma announced that the Board of Directors of the Company at its meeting held o...

Read more

20 May 2025 12:49

News

Relonchem receives marketing authorization for Sennosides 7.5 mg tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

19 May 2025 13:29

News

Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

15 May 2025 09:45

News

Marksans Pharma to conduct board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 19 May 202...

Read more

08 May 2025 15:09

News

USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection wa...

Read more

28 Apr 2025 12:58

News

Marksans Pharma gains as USFDA concludes inspection at New York unit

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturi...

Read more

28 Apr 2025 11:56

Unichem Laboratories Ltd News Hub

News

Unichem Laboratories to table results

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 22 Ma...

Read more

08 May 2025 15:32

News

Unichem Laboratories receives upgrade in credit ratings from ICRA

Unichem Laboratories announced that t ICRA, the credit rating agency has upgraded the rati...

Read more

18 Feb 2025 19:58

News

Unichem Laboratories schedules board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 6 Feb...

Read more

14 Jan 2025 14:54

News

Unichem Laboratories to discuss results

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 13 No...

Read more

25 Oct 2024 16:49

News

Unichem Laboratories to hold board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 30 Se...

Read more

23 Sep 2024 10:11

News

Board of Unichem Laboratories to consider proposal for consolidation of generic formulations biz in US

The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve i...

Read more

23 Sep 2024 09:45

SWOT Analysis Of Unichem Laboratories Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Unichem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Unichem Laboratories Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Unichem Laboratories Ltd?

Market cap of Marksans Pharma Ltd is 11,306 Cr while Market cap of Unichem Laboratories Ltd is 4,289 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Unichem Laboratories Ltd?

The stock performance of Marksans Pharma Ltd and Unichem Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Unichem Laboratories Ltd?

As of May 22, 2025, the Marksans Pharma Ltd stock price is INR ₹249.5. On the other hand, Unichem Laboratories Ltd stock price is INR ₹609.2.

How do dividend payouts of Marksans Pharma Ltd and Unichem Laboratories Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Unichem Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions